Genetic Testing for Neurofibromatosis Type 1
Comprehensive genetic testing for NF1 should include sequencing of the entire NF1 gene combined with deletion/duplication analysis using multiplex ligation-dependent probe amplification (MLPA), and in cases where blood testing is negative but clinical suspicion remains high, tumor tissue analysis should be performed to detect somatic mosaicism. 1
Testing Strategy Algorithm
First-Line Testing Approach
Perform comprehensive NF1 gene sequencing using next-generation sequencing (NGS) methods, which can detect point mutations, small insertions/deletions, and splice-site variants with a detection rate of approximately 77% of pathogenic variants 2, 3
Simultaneously conduct MLPA testing to identify large deletions or duplications, which account for approximately 23% of NF1 mutations that would be missed by sequencing alone 3, 4
This combined approach achieves a mutation detection rate of 92.1% in patients meeting clinical diagnostic criteria 2
Enhanced Detection Methods
Long-read sequencing (LRS) technology represents an emerging superior approach, achieving diagnostic yields of 92.1% in pediatric NF1 cases and demonstrating better detection of deep intronic variants (such as c.5812+332A>G) that are missed by standard exome sequencing 5
RNA-level analysis is critical when DNA sequencing identifies potential splice-site variants, as some missense mutations actually create aberrant splicing sites that function as nonsense mutations 4
Special Considerations for Mosaic Cases
When to Suspect Mosaicism
Patients presenting with milder or segmental phenotypes (café-au-lait macules limited to one body region, fewer neurofibromas) 6
Negative blood-based genetic testing despite clinical features suggestive of NF1 6
Testing Strategy for Suspected Mosaicism
Obtain tumor tissue (neurofibroma) for genetic analysis when blood testing is negative, as pathogenic variants may only be detectable in affected tissue 3, 6
Frozen tumor samples provide improved detection of somatic mosaicism compared to blood samples 3
This approach is particularly important because mosaic NF1 has reduced transmission risk and different genetic counseling implications 6
Clinical Context for Testing
The 2021 revised diagnostic criteria now incorporate genetic testing as a diagnostic criterion for NF1, making molecular confirmation increasingly important 7. Testing is particularly valuable in:
- Pediatric patients with isolated café-au-lait macules who don't yet meet full clinical criteria 5
- Parents of children newly diagnosed with NF1 to determine inheritance pattern 1
- Prenatal or preimplantation genetic diagnosis for families with known pathogenic variants 8
- Differentiating NF1 from Legius syndrome, which has phenotypic overlap in young patients with pigmentary findings 7
Critical Pitfalls to Avoid
Do not rely solely on exome sequencing, as it misses large deletions/duplications and deep intronic variants that are detectable by MLPA and long-read sequencing 2, 5
Do not stop at DNA-level analysis for suspected splice-site variants; RNA analysis is essential to determine actual effects on transcription 4
Do not conclude testing is negative based on blood samples alone in patients with segmental or mild features; tumor tissue analysis may be necessary 6
Be aware that Japanese populations may have higher incidence of large NF1 deletions with unique profiles compared to European populations 4
Impact on Mortality and Morbidity
Early genetic confirmation is clinically significant because NF1 is associated with 8-15 year reduction in life expectancy due to malignant peripheral nerve sheath tumors (MPNST) and cardiovascular causes 1. The cumulative risk of MPNST reaches 8.5% by age 30,12.3% by age 50, and 15.8% by age 85, with standardized mortality ratios exceeding 2,000 1. Genetic confirmation enables appropriate surveillance protocols and coordination with specialized NF1 clinics 1.